Table 2

Antitumor activity of Irofulven against pediatric tumor xenografts

TumorDose level (mg/kg)
7.04.63.02.01.3a
DAOY+++++++++++++++++++++++++
D283++++++++++++++++++++++a
SJ-BT12ND+++++/−aaa
SJ-BT16+++++++++++++a
SJ-BT27ND++++++++++++++++
SJ-BT29++++++++++++aNDND
SJ-BT33aaaaa
SJ-BT34++++++++++++++++++NDND
SJ-BT36++++++++++++++++++++++a
SJ-BT37+++++++++++++++aa
SJ-BT40++++++++++a+aa
SJ-GBM2+++++++++++++aNDND
NB-1771NDND+aa
NB-1382+++++++++++aNDND
NB-1643++++++++++++++++NDND
NB-1691+++++++++++aND
Rh18+++++++++++++++++++
Rh28++++++++++++++++++++++++++
Rh30NDNDND++++++++++++
Rh36++++++++++aa
CR+PR/total14/1614/188/193/151/14
  • a Growth inhibition not significant (P > 0.05). All other results were significantly different from controls (P < 0.05).

  • b Response criteria: ++++++, CR maintained at week 12 (no regrowth by week 12); +++++, CR with regrowth by week 12; ++++, PR (≥50% regression); +++, growth stasis; ++, growth inhibition equals 2 tumor-volume doubling times; +, growth inhibition equals 1 tumor-volume doubling time; −, no growth inhibition; and ND, not determined.